Oct. 7 [Overview]

Targeting c-MET in Human Cancer George F. Vande Woude, PhD Distinguished Scientific Fellow, Van Andel Research Institute, USA

Oct. 7 [Session I] Functional and Structural Biology of c-Met

	Wnt and Met Signaling in Stem and Cancer Stem Cells Walter Birchmeier, PhD Professor, Research Group Leader, Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany
	Structure/Function of HGF/SF and MET Ermanno Gherardi, PhD Principal Investigator, Medical Research Council(MRC) Contre, University of Cambridge, UK
	VEGF Regulates Tumor Invasion Through c-Met Signaling Gabriele Bergers, PhD Professor, Department of Neurosurgery, University of California, San Francisco, USA
	c-Met Signaling and Glioma Cancer Stem Cell Phenotypes Do-Hyun Nam, MD, PhD Professor, Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Oct. 7 [Session II] Clinical Significance of c-Met

	c-Met as a Therapeutic Target in Gastric Cancer Sun Young Rha, MD, PhD Professor, Division of Medical Oncology, Department of Internal Medicine Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
	Translational Research on INC280, A Selective Small Molecule inhibitor of c-Met Yao Yao, PhD Leader of Biomarkers Oncology Translational Medicine Novartis Institutes for Biomedical Research, China
	The MET Oncogene: from molecular biology to the clinic Paolo M. Comoglio, MD Director, Institute for cancer Research at Candiolo, Italy
	Role of Clinical Trial Center for Future Medicine Young Suk Park, MD, PhD Professor, Divisionof Pulmonary & Criticalcare Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
	Introduction of Institute for Refractory Cancer Reseach in Samsung Medical Center Do-Hyun Nam, MD, PhD Professor, Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Oct. 8 [Overveiw]

c-Met and Tumor Cell Reprogramming John J. Laterra, MD, PhD Johns Hopkins, USA

Oct. 8 [Session III] Targeting c-Met: Small Molecules & Antibodies

	The Development of Crizotinib for Molecularly Targeted Patient Populations James G. Christensen, PhD Director of Precision Medicine, Oncology Research Unit, Pfizer La Jolla Labs, USA
	Targeting HGF/c-Met Signaling with Rilotumumab (AMG 102), a Fully Human Monoclonal Antibody Against HGF: From Discovery Research to Phase 2 Clinical Activity Teresa Burgess, PhD Director, Oncology Research, Amgen, USA
	LA480, a c-Met Antibody with Neutralization and Internalization Properties, Inhibits HGF-dependent and HGF-Independent c-Met Pathway Activation and Tumor Growth Ling Liu, PhD Research Advisor, Biotech Discovery Research, Lilly, USA

Oct. 8 [Session IV] Targeting c-Met: Companion Diagnostics

	Prediction of Benefit from Targeted Therapies for Breast Cancer Soonmyung Paik, MD, PhD Director, Division of Pathology, NSABP, USA Director, Samsung Cancer Research Institute, Seoul, Korea
	Companion Diagnosis for MET: Guiding Therapy Decisions Yoon-La Choi, MD, PhD Assistant professor, Department of pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
	Avatar Mice: Glioblastoma Animal Models Closely Mirror Individual Tumors Kyeung Min Joo, MD, PhD Assistant Professor, Department of Anatomy, Seoul National University College of Medicine, Seoul, Koea
	Generation and functional characterization of a novel c-Met antibody Ho Yeong Song, PhD VP of Therapeutic Antibody Group, Samsung Advanced Institute of Technology, Koea

Oct. 8 [Panel Discussion] Future directions for c-Met in the drug development

Symposium Highlights Paolo M. Comoglio, MD Director, Institute for cancer Research at Candiolo, Italy